Compare ADMA Biologics Inc (ADMA) vs Shell PLC (SHEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Shell PLC — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Shell PLC trades at $82.05 (market cap $220.29B). The key difference: Shell PLC is far larger — about 103.4× ADMA Biologics Inc's market cap, and Shell PLC pays a 3.81% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SHEL | |
|---|---|---|
Market Cap | $2.13B | $220.29B |
Sector | Health | Energy |
52-Week High | $20.38 | $94.15 |
52-Week Low | $7.60 | $70.28 |
Enterprise Value | $2.20B | $272.82B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Shell (SHEL) trades at $81.99, up 5.09% on the day, with strong analyst support showing 69% buy ratings and a $112.10 consensus price target. The stock shows attractive valuation metrics with P/E of 12.17 and P/S of 0.86, while recent Q1 2026 earnings beat expectations. However, technical indicators signal bearish momentum despite positive news about stronger gas trading performance and improved refining margins ahead of Q2 results.
Shell presents a compelling value opportunity with solid profitability (7.01% net margin) and strong cash flow generation, though faces headwinds from declining revenue trends and geopolitical risks affecting production. The company's strategic focus on LNG growth and portfolio optimization supports long-term prospects, but investors should monitor execution risks and oil price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
